BR9709529A - Fragmentos de leptina (proteína ob) - Google Patents

Fragmentos de leptina (proteína ob)

Info

Publication number
BR9709529A
BR9709529A BR9709529A BR9709529A BR9709529A BR 9709529 A BR9709529 A BR 9709529A BR 9709529 A BR9709529 A BR 9709529A BR 9709529 A BR9709529 A BR 9709529A BR 9709529 A BR9709529 A BR 9709529A
Authority
BR
Brazil
Prior art keywords
protein
leptin fragments
leptin
fragments
Prior art date
Application number
BR9709529A
Other languages
English (en)
Portuguese (pt)
Inventor
Kamal A Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Original Assignee
Smithkline Beecham P L C Socie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Application filed by Smithkline Beecham P L C Socie filed Critical Smithkline Beecham P L C Socie
Publication of BR9709529A publication Critical patent/BR9709529A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9709529A 1996-06-06 1997-06-04 Fragmentos de leptina (proteína ob) BR9709529A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds
PCT/EP1997/002968 WO1997046585A2 (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)

Publications (1)

Publication Number Publication Date
BR9709529A true BR9709529A (pt) 1999-08-10

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9709529A BR9709529A (pt) 1996-06-06 1997-06-04 Fragmentos de leptina (proteína ob)

Country Status (15)

Country Link
EP (1) EP0912609A2 (no)
JP (1) JP2000512137A (no)
KR (1) KR20000016402A (no)
CN (1) CN1221426A (no)
AR (1) AR008765A1 (no)
AU (1) AU3337297A (no)
BR (1) BR9709529A (no)
CA (1) CA2257240A1 (no)
CZ (1) CZ397898A3 (no)
IL (1) IL127153A0 (no)
NO (1) NO985683L (no)
NZ (1) NZ332879A (no)
PL (1) PL330361A1 (no)
TR (1) TR199802534T2 (no)
WO (1) WO1997046585A2 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000007014A2 (en) 1998-07-28 2000-02-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US7208572B2 (en) * 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
EP1283878B1 (en) 2000-05-22 2005-07-27 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Receptor-based interaction trap
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
US8283307B2 (en) 2003-09-08 2012-10-09 Merck Serono Sa Treatment of fibrotic disease
EP2422807A3 (en) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
SG159551A1 (en) 2005-02-11 2010-03-30 Amylin Pharmaceuticals Inc Gip analog and hybrid polypeptides with selectable properties
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
MX2010006215A (es) 2007-12-05 2010-08-17 Astrazeneca Ab Derivados de piperazina y su uso como moduladores del receptor de leptina.
EP2229362A1 (en) 2007-12-05 2010-09-22 AstraZeneca AB Piperazines as anti-obesity agents
WO2009147211A1 (en) * 2008-06-04 2009-12-10 Biovitrum Ab (Publ) New compounds v
EP2313094A1 (en) * 2008-06-04 2011-04-27 AstraZeneca AB New pyridine derivatives as leptin receptor modulator mimetics
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
WO2011143280A2 (en) * 2010-05-11 2011-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
EP2621515B1 (en) 2010-09-28 2017-03-29 Aegerion Pharmaceuticals, Inc. A chimeric seal-human leptin polypeptide with increased solubility
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU4766596A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
CA2211656A1 (en) * 1995-01-31 1996-08-08 Margret B. Basinski Anti-obesity proteins
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CZ397898A3 (cs) 1999-04-14
PL330361A1 (en) 1999-05-10
WO1997046585A3 (en) 1998-04-23
KR20000016402A (ko) 2000-03-25
TR199802534T2 (xx) 1999-03-22
CA2257240A1 (en) 1997-12-11
AR008765A1 (es) 2000-02-23
CN1221426A (zh) 1999-06-30
NZ332879A (en) 2000-09-29
NO985683D0 (no) 1998-12-04
WO1997046585A2 (en) 1997-12-11
EP0912609A2 (en) 1999-05-06
IL127153A0 (en) 1999-09-22
NO985683L (no) 1998-12-04
JP2000512137A (ja) 2000-09-19
AU3337297A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
BR9709529A (pt) Fragmentos de leptina (proteína ob)
DE69724557D1 (de) Dokumentenanalyse
DE69722620D1 (de) Nicht-waessrige protische peptidzubereitungen
NO985680L (no) Peptidderivater
NO983849D0 (no) Peptidderivater
DE59707298D1 (de) Desodorierende zubereitungen
DK0832553T3 (da) Mejetærsker
GB9614033D0 (en) Modified protein G and fragments thereof
TR199701666A3 (tr) Sismanliga karsi proteinler
DE69925271D1 (de) Angiostatin-bindendes protein
DE69718328T2 (de) Magnetrongerät
FR2865535B1 (fr) Penetreur
DE59602924D1 (de) Knochenraspel
DE59702387D1 (de) Medizinische zange
KR970004260U (ko) 정형외과용 콜셋
BR7601137U (pt) Bone
ZA971900B (en) Modified proteins
KR970059003U (ko) 조인트용 부트
KR970064121U (ko) 마그네트론
KR980005234U (ko) 마그네트론
SE9602287D0 (sv) Novel protein and methods for its use
SE9601761D0 (sv) T-ventilförfarande
ID16704A (id) Metoda penyembuhan
UA1371S (uk) Цвях
KR970052198U (ko) 못

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.PORTANTO, INDEFIRO O PRESENTE PEDIDO.